← Eichor
Study identifier: NCT06825260 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PEG3350 vs Senna After Urogyn Surgery

Condition: Obstructive Defecation Syndrome · Postoperative Constipation  ·  Sponsor: St. Joseph's Health, New York

PhasePhase 4
Planned participants254
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersYes

About this study

The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are: What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a form of constipation, vs those taking senna in the week after urogynecologic surgery? What patient-level and procedure-level characteristics are associated with postoperative ODS, in patients taking PEG3350 vs senna? participants will: Take their randomized medication daily for seven days after surgery Fill out an ODS questionnaire before and one week after surgery Complete a daily bowel diary for 7 days after surgery

This description comes directly from the study's public registry record.

Talk to the study team

Keila S Muniz, MD  ·  631-896-7937  ·  keila.muniz@sjhsyr.org

Always discuss trial participation with your own doctor first.

Locations (1)

St. Joseph's Health HospitalSyracuse, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06825260